Notice Regarding the Start of Dosing in a Clinical Trial Aimed at Establishing a New Indication for the Oncolytic Virus Telomelysin Injection | Oncolys BioPharma Inc. (4588) timely disclosure

Worth reading

31Immaterial

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Neutral

Direction inferred from the company’s description.

Scale

times (number of combination doses)

Wording

Conditional

How definitive the wording is.

Initiation of dosing in a clinical trial aimed at a new indication for the oncolytic virus Telomelysin® injection

Subject Entity

Oncolys BioPharma Inc.

Target Locations / Products

Lower rectal cancer and anal cancer, Telomelysin® injection (development code: OBP-301)

This disclosure10/30/2026

Amount of Impact on Business Performance

Amount: Not disclosed (the impact on financial results for the fiscal year ending December 2026 is immaterial)

Accounting period in which recognized

Fiscal year ending December 2026

Impact on Earnings Forecast

The impact on financial results for the fiscal year ending December 2026 is immaterial.

Outlook

In this trial, we will evaluate efficacy and safety against localized cancer and continue to pursue the realization of a healthcare system that does not require stoma creation.

Event that occurred
Item	Details
Event name	Initiation of dosing in a clinical trial aimed at a new indication for the oncolytic virus Telomelysin® injection
Subject Entity	Oncolys BioPharma Inc.
Target Locations / Products	Lower rectal cancer and anal cancer, Telomelysin® injection (development code: OBP-301)
Amount of Impact on Business Performance	Amount: Not disclosed (the impact on financial results for the fiscal year ending December 2026 is immaterial)
Accounting period in which recognized	Fiscal year ending December 2026
Impact on Earnings Forecast	The impact on financial results for the fiscal year ending December 2026 is immaterial.
Outlook	In this trial, we will evaluate efficacy and safety against localized cancer and continue to pursue the realization of a healthcare system that does not require stoma creation.

Items this document does not state (18)

Date of occurrenceDate recognized / date notice receivedCauseType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To pursue a new indication and evaluate efficacy and safety in localized lower rectal cancer and anal cancer. In addition, to pursue the realization of a healthcare system that does not require stoma creation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.